Fosamprenavir and sodium alginate for GERD
Part of Digestive system clinical trials.
This trial tests a combination of two medicines, fosamprenavir and sodium alginate, to see if they work better than standard treatment for people with ongoing GERD symptoms. It is for adults who still have heartburn despite taking daily PPI medication.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 65 years old and have been chosen as a candidate for anti-reflux surgery.
- You have had heartburn or other GERD symptoms for at least 8 weeks while taking a daily standard dose of a PPI.
- You have had an endoscopy or pH test in the last 2 years that shows erosive esophagitis (Grade A or higher) or abnormal acid reflux.
- You have had moderate or worse heartburn on at least 2 days in the past week, and your average heartburn over the last 7 days is at least mild.
- You do not have certain other stomach conditions like functional dyspepsia, functional heartburn, or eosinophilic esophagitis.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study compares a new procedure called anti-reflux mucosal valvuloplasty (ARMV) to acid-reducing medicines (PPIs) for treating GERD. It may help people who have had reflux for a long time and need daily PPIs.
This study tests a new procedure called anti-reflux mucosal ablation to see if it helps people with long-lasting heartburn and acid reflux. It might be an option if medications haven't fully controlled your symptoms.
This Phase 2 study tests whether fosamprenavir can reduce inflammation and enzyme activity in the throat area for people with laryngopharyngeal reflux (LPR). If you still have LPR symptoms despite 3 months of twice-daily reflux medicine, this trial may offer another treatment approach.
This study tests a new wearable device (eGERD) that aims to reduce symptoms of GERD (heartburn and regurgitation). The trial will check if the device is safe and works well without needing medication.
This study tests a new topical treatment for people with chronic heartburn and acid regurgitation who don't have erosions (damage) in their esophagus. The treatment is applied directly to the affected area and may help relieve symptoms without taking daily pills.
This trial tests a new medicine called anaprazole for people with moderate to severe reflux esophagitis (chronic heartburn and damage to the food pipe). It compares anaprazole to a standard treatment to see which works better and is safer.
Hear when a new GERD trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.